The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
The drug maker's vision for 2014: fighting to keep Victoza top-of-mind with a US field force of around 3,000.
The company's latest numbers show generics continue to pummel sales. Former GSK-er Marc Dunoyer replaces departing CFO Simon Lowth.
The company says it recaptured some former advertisers and that third-quarter traffic is up compared with last year.
The company's hep. C drug Incivek peaked in 2011. Competition and pipeline drugs have forced the company to regroup.
Third-quarter earnings did not stir up analysts, who were more focused on the pipeline and Pfizer's future organizational plans.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
Sales of its breast cancer treatments boosted totals for the first nine months of 2013, along with diagnostics, which saw a 3% increase over last year.
The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.
The CEO says Sanofi's patent-loss turnaround is coming.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
Analyst Seamus Fernandez writes that Merck needs to undergo a deep overhaul, continuing the summer narrative that has enveloped Pfizer and Novartis.
Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.
Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.
The company narrowed its second quarter loss, but said its national TV campaign is driving an uptick in consumer interest.
David Schlanger is the company's new chief executive, a role he's filled on an interim basis since May.
This is the second addition this year and brings the company's contracted sales force to 260.
The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.
Pfizer said 2017 is the earliest the firm could split up. Meanwhile, sales dropped 7% year-on-year.
Quarterly sales fell 11% compared to the same period last year. The company plans on weathering a continued flow of patent losses with a narrower R&D focus.
Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.
Biogen Idec raised its full-year guidance on Tecfidera launch sales, as the MS market continues its growth trajectory.
The Indiana drug maker logged a 6% sales increase over the same period last year. Higher prices were responsible for the majority of the growth.
GlaxoSmithKline second-quarter sales rose 2% over the same period last year. CEO Andrew Witty says it is too early to tally the impact of China's corruption allegations.
China's industry investigation widens beyond GlaxoSmithKline; PhRMA's European equivalent rallies patient groups to fight transparency; Biogen Idec says a patient's death is not linked to Tecfidera; parents swap walk-in clinics for office visit; Roche continues its CEO hunt; and Forest logs 6% sales growth.
Lundbeck and Otsuka prime Alzheimer's med for Phase III trials; Abbott reports Q2 results; and an FDA panel shrugs off Merck's muscle relaxant for another day.
High points included an OTC rebound and strong performances from pharma.
Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor.
The CEO's unexpected departure is part of the health information brand's latest changes. On the table: possible acquisitions. In progress: a new federal contract and new website content. Ignored: if the company wants to be bought.
The portal announced Tuesday that Cavan Redmond, who took the top job there just weeks shy of one year back, is no longer with the company.